Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuromuscular
•
Neuro-immunology
How does lack of success of rituximab treatment affect your decision to trial anti-CD19 therapies like inebilizumab?
e.g. for NMO and MG
Related Questions
What is the role of skin biopsy for evaluating small fiber neuropathy in patients with rheumatic disease who have treatment recalcitrant pain?
What therapy do you recommend in situations where IV steroids and IVIg do not help patients with GABA-A encephalitis?
In a patient with strong serologic evidence of SLE presenting with isolated bilateral lower limb sensorimotor neuropathy, normal neuroimaging, and CSF, would you initiate cyclophosphamide with pulse-dose steroids upfront, or reserve escalation (e.g., plasma exchange or immunosuppressants) for cases refractory to steroids?
When do you obtain nerve biopsy to evaluate for vasculitic neuropathy in patients with distal symmetric polyneuropathies?
When would you use ofatumumab for anti-NMDAR autoimmune encephalitis?
How do you counsel patients interested in primary prevention of MS?
Which non-pharmacologic treatments for neuropathic pain have you found most effective?
In a patient with prior biopsy-proven IgG4-related pachymeningitis who develops recurrent neurologic symptoms years after discontinuing immunosuppression, how do you determine whether this represents relapse versus alternative etiologies?
When should MOG-Ab be tested in patients with suspected autoimmune encephalitis with seizures and normal MRI?
How do you counsel patients with dermatomyositis on sun protection?
